- Home
- LEE vs CUE Comparison
LEE vs CUE Comparison
Compare LEE & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEE | CUE |
|---|---|---|
| Founded | 1890 | 2014 |
| Country | United States | United States |
| Employees | 2500 | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 49.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | LEE | CUE |
|---|---|---|
| Price | $4.01 | $0.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 17.5K | ★ 249.2K |
| Earning Date | 11-26-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $562,341,000.00 | $7,100,000.00 |
| Revenue This Year | $5.48 | $36.58 |
| Revenue Next Year | N/A | $32.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.70 | $0.47 |
| 52 Week High | $16.84 | $1.75 |
Technical Indicators
Market Signals| Indicator | LEE | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 39.28 | 27.37 |
| Support Level | $3.90 | $0.47 |
| Resistance Level | $4.43 | $0.51 |
| Average True Range (ATR) | 0.38 | 0.05 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 2.73 | 2.67 |
Price Performance
Historical ComparisonAbout LEE Lee Enterprises Incorporated
Lee Enterprises Inc is a local news publication company in the United States. It is a digital-first subscription business providing local markets with valuable, high-quality, trusted, intensely local news, information, advertising, and marketing services. The product portfolio of the company includes digital subscription platforms, daily, weekly, and monthly newspapers, and niche products, all delivering original local news and information as well as national and international news. The products offer digital and print editions, and content and advertising are available in real-time through the websites and mobile apps.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.